Perifosine-mediated Akt inhibition in NETs

Aberrant Akt activity is evident in most gastroenteropancreatic neuroendocrine tumours (NETs). Several phase III trials are underway which target mTOR signalling in the PI3K/Akt/mTOR pathway. In this study, Zitzmann and colleagues demonstrate that perifosine potently inhibits Akt phosphorylation and cell viability in three human NET cell lines of pancreatic, small intestine, and bronchial origin. They suggest selective targeting of Akt1 and Akt3 isoforms could be particularly effective in NET treatment. Zitzmann et al. (2012) Endocrine-Related Cancer 19 423–434.

Read the full article at: DOI: 10.1530/ERC-12-0074